Congenital intrahepatic portosystemic shunt presenting with mucocutaneous bleeding

Sajani Galappaththi¹, Shaman Rajindrajith¹,², *Sachith Mettananda¹,²

Sri Lanka Journal of Child Health, 2020; 49(4): 396-398
DOI: http://dx.doi.org/10.4038/sljch.v49i4.9275
(Key words: portosystemic shunt, coagulopathy, hyperammonaemia)

Introduction
Congenital portosystemic shunts (CPSS) are rare vascular abnormalities characterized by complete or partial shunting of portal blood into systemic veins bypassing the liver¹. Anatomically, CPSS are classified into extra- and intra-hepatic shunts based on their location². Some of these shunts are asymptomatic and resolve spontaneously whereas others cause marked metabolic abnormalities affecting a variety of organ systems³. Common presentations of CPSS include neonatal cholestasis, encephalopathy, liver tumours and hepato-pulmonary syndrome; however, severe coagulopathy is rare⁴. Here, we report a child with congenital intrahepatic portosystemic shunt presenting with a bleeding diathesis.

Case report
An 8-year old Sri Lankan boy presented with epistaxis and ecchymosis of 3 days duration. He started to have a few ecchymotic patches on the back which then progressed throughout the body during the past three days. There was no haematemesis, melaena, haematuria or evidence of bleeding into any other organs. He also complained of unsteady gait and excessive sleepiness which lasted 24 hours before resolving spontaneously.

At 1 year of age, he has had an episode of nephrotic syndrome which was complicated by haematuria and hypertension that was later diagnosed as mesangio-proliferative glomerulonephritis by renal biopsy. Nonetheless, he did not have further relapses. At five years, he developed an afebrile generalized tonic clonic seizure without an identifiable provoking factor. He subsequently had three further seizures of similar semiology and was started on sodium valproate 20mg/kg/day for idiopathic generalized epilepsy. Electroencephalogram was normal. He was born to non-consanguineous parents with a birth weight of 3.3kg and required phototherapy for neonatal jaundice. Growth and childhood development were age appropriate except that he was a slow learner with poor school performance. He had no family history of liver diseases or sudden and unexplained deaths.

On examination, his growth parameters were within normal limits. He had multiple ecchymotic patches on the body but did not have any peripheral stigmata of chronic liver disease, hepatosplenomegaly or ascites. The remainder of the physical examination, including nervous system, was clinically normal.

The full blood count revealed: haemoglobin 11.1g/dL, haematocrit 32.1%, white blood cell count 9.8x10⁵/µL (neutrophils 20%, lymphocytes 73%) and platelet count 19x10⁵/µL.

Liver function tests revealed: total bilirubin 39µmol/L (normal 1-24µmol/L), direct bilirubin fraction 33%, aspartate transaminase 54U/L (normal 10-40U/L), alanine transaminase 13U/L (normal 10-40U/L), alkaline phosphatase-185U/L (normal 104-345U/L), gamma glutamyl transferase 17U/L (normal 9-48U/L) and serum total protein 5.3g/dl (albumin 2.7g/dL, globulin 2.6g/dL). The erythrocyte sedimentation rate, C-reactive protein and renal functions were normal.

His coagulation profile was deranged. His prothrombin time (PT) was 22s (normal 12-16s) with an INR of 1.7 while the activated partial thromboplastin time (APTT) was 39.3s (normal 24-35s). The thrombin time was normal (19.1s). PT and APTT following 50:50 correction were normal (15.7s and 29.9s respectively). His fasting plasma

¹Colombo North Teaching Hospital, Ragama, Sri Lanka, ²Department of Paediatrics, University of Kelaniya, Sri Lanka
*Correspondence: sachithmetta@yahoo.com
orcid.org/ 0000-0002-0760-0418
(Received on 15 March 2019: Accepted after revision on 26 April 2019)
The authors declare that there are no conflicts of interest
Personal funding was used for the project.
Open Access Article published under the Creative Commons Attribution CC-BY License
ammonia level was 74µmol/L (normal <40µmol/L).

Abdominal ultrasonography showed a portosystemic shunt between the right branch of portal vein and inferior vena cava (IVC) with associated chronic parenchymal changes of the right lobe of the liver. Contrast enhanced computed tomography of abdomen with portal venography confirmed the presence of directly communicating intrahepatic portosystemic shunt between the right portal vein and the IVC (Figure 1) with faintly visible focal lesions in segment VIII of the liver during arterial phase. Echocardiogram did not show evidence of pulmonary hypertension. The child is awaiting surgical closure of the shunt.

Discussion

CPSS was first described by John Abernethy in 1793 and can be intrahepatic or extrahepatic. Extrahepatic CPSS is further subdivided into types 1 and 2 based on the patency or apparent non patency of the portal trunk and intrahepatic portal system. CPSS can cause a wide variety of clinical manifestations in older children including encephalopathy, liver tumours, hepato-pulmonary syndrome and pulmonary hypertension but coagulation abnormalities are sparsely reported.

The most unusual feature in our patient is that he came to medical attention following mucocutaneous bleeding. Investigations confirmed coagulatory derangement in both intrinsic and extrinsic pathways along with severe thrombocytopenia. Although inadequate production of clotting factors due to hepatic derangement could explain the coagulopathy in this child, it will not clarify the severe thrombocytopenia. Thrombocytopenia could be due to splenic sequestration of platelets but, our patient neither had splenomegaly nor portal hypertension.

Therefore, we believe that deranged PT, INR, APTT and severe thrombocytopenia of this child are probably due to a consumptive coagulopathy within the shunt.

Neurological manifestations of CPSS include irritability, dyslexia, lethargy, EEG abnormalities, extrapyramidal signs, and epilepsy. These manifestations are most likely to be due to bypass of hepatic detoxifying mechanisms of toxic compounds, including ammonia, leading to increased plasma levels. Our patient did not have overt encephalopathy but had four seizures which may have been provoked by episodes of hyperammonaemia.

CPSS can also cause nodular lesions, focal nodular hyperplasia, hepatocellular adenoma, hepatocellular carcinoma and hepatic sarcoma in affected patients. Focal nodular hyperplasia shows homogeneous strong enhancement in the arterial phase. The faintly visible liver focal lesions during the arterial phase, which was seen in our patient, are most likely to be due to focal nodular hyperplasia. Other associated feature of CPSS includes intrauterine growth retardation, membrano-proliferative glomerulonephritis, congestive heart failure, pancreatitis, pulmonary hypertension, hepato-pulmonary syndrome and autoimmune disorders of which our patient had glomerulonephritis in the past. In summary, this case report highlights an unusual presentation with coagulopathy of a rare anatomical malformation involving the portal venous system.

References

1. Alonso-Gamarra E, Parrón M, Pérez A, Prieto C, Hierro L, López-Santamaría M. Clinical and Radiologic Manifestations of Congenital Extrahepatic Portosystemic Shunts: A Comprehensive Review. Radiographics 2011; 31(3): 707-22. https://doi.org/10.1148/rg.313105070 PMid: 21571652

2. Witters P, Maleux G, George C, Delcroix M, Hoffman I, Gewillig M, et al. Congenital veno-venous malformations of the liver: widely variable clinical presentations. Journal of Gastroenterology and Hepatology 2008; 23(8 Pt 2):e390-4. https://doi.org/10.1111/j.14401746.2007.05156.x PMid: 17868331

3. Papamichail M, Pizanias M, Heaton N. Congenital portosystemic venous
Congenital intrahepatic portosystemic shunt... Sri Lanka Journal of Child Health, 2020; 49(4): 396-398

shunt. European Journal of Pediatrics. 2017; 177(3):285-94. https://doi.org/10.1007/s00431-017-3058-x PMid: 29243189 PMCid: PMC5816775

4. Bernard O, Franchi-Abella S, Branchereau S, Pariente D, Gauthier F, Jacquemin E. Congenital portosystemic shunts in children: recognition, evaluation, and management. Seminars in Liver Disease 2012; 32(4):273-87. https://doi.org/10.1055/s-0032-1329896 PMid: 23397528

5. Abernethy J. Account of two instances of uncommon formation in the viscera of the human body: From the Philosophical Transactions of the Royal Society of London. Medical Facts and Observations 1797; 7:100-8. PMid: 29106224 PMCid: PMC5111139

6. Morgan G, Superina R. Congenital absence of the portal vein: two cases and a proposed classification system for portasystemic vascular anomalies. Journal of Pediatric Surgery 1994; 29(9):1239-41. https://doi.org/10.1016/0022-3468(94)90812-5

7. Timpanaro T, Passanisi S, Sauna A, Trombatore C, Pennisi M, Petrillo G, et al. Congenital portosystemic shunt: our experience. Case Reports in Pediatrics 2015; 2015:691618. PMid: 25709849 PMCid: PMC4332460

8. Bas S, Guran T, Atay Z, Haliloglu B, Abali S, Turan S, et al. Premature pubarche, hyperinsulinemia and hypothyroxinemia: novel manifestations of congenital portosystemic shunts (Abernethy malformation) in children. Hormone Research in Paediatrics 2015; 83(4):282-7. https://doi.org/10.1159/000369395 PMid: 25676144

9. Chandrasekharan R, Pullara SK, Thomas T, Kader NP, Moorthy S. Congenital intrahepatic portosystemic shunts: Imaging findings and endovascular management. Indian Journal of Radiology and Imaging 2016; 26(1):92-4 https://doi.org/10.4103/0971-3026.178349 PMid: 27081230 PMCid: PMC4813081